PATENT CLAIM ANALYSIS

Application Number: 16068629
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["424", "133100"]

Abstract:
An embodiment of the invention relates to the use of stabilized cancer peptide fragments derived from Protocadherin FAT1 for the diagnosis of cancers, particularly pancreatic cancer. A method for the detection of cancer, severity of cancer, and/or effectiveness of a therapeutic regimen includes detecting and/or measuring the amount of Protocadherin FAT1 peptide fragments present in the biological sample of a subject.

Claim (Index 51):
The method of  claim 44 , wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, colon cancer, endometrial carcinoma, esophagus squamous cell carcinoma, glioma, hepatocellular carcinoma, infiltrating ductal breast carcinoma, larynx cancer, lung squamous cell carcinoma, melanoma, mucinous cystadenocarcinoma of ovary, pancreatic cancer, prostate cancer, renal cell carcinoma, small bowel malignant stromal tumor, and stomach adenocarcinoma.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 95.0
- Lexical Diversity: 1.60976
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14800162', '13384014', '13464174', '14671062', '13813680']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7840946103901003
- 35 USC 102 Novelty (BERT): 0.5406316417412117
- Combined Prediction Score: 0.7597483135252114
- Mean Citation Score: 313.977452
- Max Citation Score: 393.46048
- Similarity Product: 321.52082656234745

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test